Compare PCLA & PMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCLA | PMI |
|---|---|---|
| Founded | 2008 | 1981 |
| Country | Japan | United States |
| Employees | 55 | 75 |
| Industry | Building Products | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 14.1M |
| IPO Year | N/A | N/A |
| Metric | PCLA | PMI |
|---|---|---|
| Price | $6.73 | $0.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 68.5K | ★ 30.1M |
| Earning Date | 02-13-2026 | 06-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.11 |
| 52 Week High | $14.10 | $13.68 |
| Indicator | PCLA | PMI |
|---|---|---|
| Relative Strength Index (RSI) | 57.50 | 36.17 |
| Support Level | $6.10 | $0.15 |
| Resistance Level | $8.00 | $0.27 |
| Average True Range (ATR) | 1.36 | 0.04 |
| MACD | -0.27 | 0.01 |
| Stochastic Oscillator | 43.13 | 1.94 |
PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing the SynCardia TAH, an implantable total artificial heart system. The company is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including the SynCardia TAH, which is designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH replaces both the left and right ventricles as well as all four heart valves.